Navigation Links
Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
Date:10/6/2010

SAN DIEGO, Oct. 6 /PRNewswire/ -- Sangart, Inc., today announced that it has been awarded a $1.1 million grant from the U.S. Department of Defense to support the development of its novel product platform based on the MP4 molecule, an investigational biopharmaceutical product designed to enhance the perfusion and oxygenation of oxygen-deprived tissues and provide targeted oxygen delivery to the capillaries in severely injured trauma patients. This award funds further pre-clinical development of the MP4 molecule in traumatic hemorrhage and ischemia in support of its current and future clinical programs.  

The award is being issued as part of the Defense Medical Research and Development Program, which provides grants in support of research designed to advance state-of-the-art solutions for world-class medical care for United States warfighters.

"We are honored to receive this grant from the Department of Defense," said Brian O'Callaghan, President and Chief Executive Officer of Sangart. "This grant supports our efforts in continuing the development of medicines designed to enhance the delivery of oxygen to tissues and organs that are oxygen deprived and supports our continued commitment to bringing new treatment options for warfighters and civilian patients suffering an acute traumatic injury."

Physical trauma is a serious injury with profound and lasting consequences. Traumatic injuries, including both penetrating trauma injuries such as bullet and knife wounds and blunt trauma from car accidents and falls, cause the death of over 5 million people each year world-wide. According to the Centers for Disease Control and Prevention (CDC), unintentional injury kills more people between the ages of one and 44 than any other disease or illness. Uncontrolled post-traumatic bleeding and resultant shock is the leading cause of potentially preventable death among military and civilian trauma patients.

About MP4Sangart's product platform is based on the MP4 molecule, an investigational biopharmaceutical product designed to enhance the perfusion of oxygen-deprived (ischemic) tissues and provide targeted oxygen delivery in the capillaries. Using a novel pegylation approach, Sangart produces the MP4 molecule designed at the optimal oxygen affinity, diffusion potential and molecular size to perfuse capillaries and target oxygen delivery to tissues specifically at risk of ischemia.

About SangartSangart is a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen delivery. Based on more than a decade of research, Sangart has refined the pegylation of human hemoglobin to create a molecule, MP4, with the ability to carry oxygen through the circulatory system to prevent and treat ischemia.

To learn more about Sangart, please visit the company's website at www.sangart.com.Media Contact:Marites Cristobal CoulterEdelman Public Relations

Office: 323-202-1424Marites.Cristobal@edelman.com

Cell: 415-819-2214
'/>"/>

SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients
2. Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease
3. Sangart, Inc. Completes Series F Funding Round
4. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
5. EarlySenses EverOn(R) Central Display Station (CDS) Receives FDA Clearance
6. Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIREā„¢ Label-Free Detection Technology for Proteomics
7. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for New Collagen Dental Membrane Based on Porcine Collagen Platform Technology
8. Xiaoguang Meng receives honorary master of engineering from Stevens
9. AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy
10. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
11. NephRx Corp. Receives Orphan Drug Designation for NX001 for Prevention of Delayed Kidney Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):